Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Grants Orphan Drug Designation for Vivet's Gene Therapy for CTX
Details : VTX-806, an Adeno-associated viral (AAV) vector encoding human CYP27A1 is being investigating for the treatment of Cerebrotendinous Xanthomatosis (CTX).
Brand Name : VTX-806
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 05, 2024
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vivet Doses First Patient in Cohort 2 of Phase 1/2 GATEWAY Trial for Wilson Disease
Details : VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) gene therapy, which is being evaluated for the treatment of wilson disease.
Brand Name : VTX-801
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 08, 2024
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : French Government
Deal Size : $5.2 million
Deal Type : Funding
Vivet Receives EUR 4.9 Million for Gene Therapy Development
Details : Vivet will use funds to develop VTX-806, aiming to halt or reverse disease progression in cerebrotendinous xanthomatosis patients.
Brand Name : VTX-806
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : VTX-806
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : French Government
Deal Size : $5.2 million
Deal Type : Funding
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Vivet Therapeutics’ VTX-801 Gets FDA Fast Track Designation for Wilson Disease
Details : VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease.
Brand Name : VTX-801
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 12, 2021
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the progr...
Brand Name : VTX-803
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 12, 2021
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Recipient : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threa...
Brand Name : VTX-801
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : VTX-801
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Recipient : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VTX-803 is Vivet’s second gene therapy product to be granted Orphan Drug Designation. VTX-803 is currently under IND-enabling studies and initiation of clinical development is planned for the second part of 2021 in both the US and the EU.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 01, 2020
Lead Product(s) : VTX-803
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?